Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

This study is testing whether adding the immunotherapy drug pembrolizumab to standard pre-surgery chemotherapy (albumin paclitaxel + carboplatin) improves outcomes for people with stage II or III esophageal squamous cell cancer that can be surgically removed. **You may be eligible if...** - You have been diagnosed with stage II or III squamous cell cancer of the esophagus that is eligible for surgery - You have not previously received any treatment for esophageal cancer - You are between 18 and 75 years old - Your blood counts, liver, and kidney function meet the study's lab requirements - Your doctors expect surgery can fully remove the cancer - You have a good general health status (ECOG 0-1) **You may NOT be eligible if...** - You have previously received surgery, chemotherapy, radiation, or immunotherapy for esophageal cancer - You are pregnant or breastfeeding - You have active autoimmune diseases requiring treatment - You have poorly controlled heart disease - You have had prior treatment with a PD-1/PD-L1 immunotherapy drug - You are allergic to any medications in the study Talk to your doctor to see if this trial is right for you.